Xenon (XENE)
NASDAQ:XENE
Want to see XENE full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-1.13Last Year’s EPS
-1.07Same Quarter Last Year
Strong Buy
Based on 19 Analysts Ratings
Earnings Call Summary
Q1 2026
Earnings Call Date:May 07, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call conveyed overwhelmingly positive clinical and corporate momentum: a highly favorable XTOL-2 Phase 3 data set with strong efficacy, long-term seizure freedom signals, a consistent safety profile, and a fortified balance sheet ($1.3B) supporting operations into 2029. The company has a clear regulatory path (NDA guidance for 2026) and active commercial and payer engagement. Remaining uncertainties are largely execution and timing risks (regulatory scheduling, commercial launch logistics, payer access) and limited near-term public granularity on Phase 1 pain data. On balance, the highlights are substantial and materially outweigh the modest operational and timing risks discussed.Company Guidance
Exceptional Phase 3 XTOL-2 Efficacy
XTOL-2 met its primary endpoint with median percent change (MPC) in monthly focal seizure frequency of 53.2% (25 mg), 34.5% (15 mg) versus 10.4% for placebo; placebo-adjusted MPC for 25 mg ~42.8 percentage points. Company described this as exceeding expectations and surpassing prior Phase 2b results.
Strong Responder and Seizure Freedom Signals
Dose-dependent increases in responder rates including >=75% and >=90% reductions; 100% responder (RR100) for 25 mg was 6.5% over 12 weeks, increasing to 11.3% over the last 6 weeks and 13.7% over the last 4 weeks—evidence of building efficacy over time.
Robust Long-Term OLE Outcomes
48-month open-label extension showed a 91% reduction in monthly seizures for patients treated ≥48 months. Patients entering on 1–2 ASMs had a 100% reduction vs 82% for those on 3 ASMs. Among patients treated ≥48 months, ~40% were seizure-free for ≥12 months and ~25% were seizure-free for ≥2 years.
Consistent and Manageable Safety Profile
Safety and tolerability were consistent across XTOL and XTOL-2 with most common treatment-emergent adverse events being dizziness, somnolence, headache, and fatigue. Company cites >800 patient-years of safety/exposure data and characterizes profile as consistent with well-tolerated CNS-active ASMs.
Clear Regulatory and Commercial Pathway
Company plans NDA submission for AZK in 2026, anticipates a standard FDA review (~12 months) plus DEA scheduling (~3 months), implying expected launch in 2027 or early 2028 if timing holds. Pre-NDA interactions and continued FDA engagement planned.
Strong Balance Sheet and Funding Runway
Completed $747.5 million financing in Q1; cash, cash equivalents, and marketable securities of $1.3 billion vs $586 million at Dec 31, providing runway into 2029 to support commercial launch and ongoing programs.
Progress Across Broader Pipeline
Three Phase 3 depression studies (EXNOVA-2, EXNOVA-3, EXEDE) continue to enroll with EXNOVA-2 topline expected in 2027. First-in-human studies for pain programs XEN1701 (Nav1.7) and XEN1120 (Kv7) expected to complete this year with intent to advance to Phase II PoC in acute pain. Nav1.1 (Dravet) IND-enabling studies ongoing with strong preclinical data presented.
Strong Scientific and HCP Engagement
XTOL-2 data were accepted as a late-breaking oral presentation at AAN; company reported extensive positive feedback from hundreds of epileptologists and neurologists emphasizing efficacy magnitude, rapid onset, no titration, once-daily dosing, and no dose adjustments for other ASMs.
XENE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
XENE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $56.00 | $56.44 | +0.79% |
Feb 26, 2026 | $44.92 | $43.23 | -3.76% |
Nov 03, 2025 | $41.12 | $39.09 | -4.94% |
Aug 11, 2025 | $34.11 | $35.99 | +5.51% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Xenon (XENE) report earnings?
Xenon (XENE) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Xenon (XENE) earnings time?
Xenon (XENE) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XENE EPS forecast?
XENE EPS forecast for the fiscal quarter 2026 (Q2) is -1.13.